Previous close | 5.57 |
Open | 5.46 |
Bid | 5.94 x 900 |
Ask | 0.00 x 800 |
Day's range | 5.46 - 6.31 |
52-week range | 5.23 - 22.49 |
Volume | |
Avg. volume | 437,868 |
Market cap | 67.341M |
Beta (5Y monthly) | 1.59 |
PE ratio (TTM) | N/A |
EPS (TTM) | -6.23 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 35.25 |
Annovis Bio's on Monday reported data that showed its Alzheimer's disease drug failed to show statistical significance in meeting the goals of a mid-stage trial sending its shares tumbling as much as 60%. The trial tested the drug buntanetap in patients with mild-to-moderate Alzheimer's disease (AD) along two scales assessing cognition and cognitive dysfunction. In a press release, the company said a "post-hoc" analysis of the trial data had shown statistically significant results in improving cognition function scores along an Alzheimer's disease scale in a subgroup of patients who had mild disease and who tested positive for certain disease biomarkers.
Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild ADImprovement in cognition measured by ADAS-Cog 11 at three months is 3.3 points as compared to 0.3 for placebo, consistent with our previous Phase II AD/PD and Discover studies Plasma Tau protein levels are reduced, consistent with our previous Phase II biomarker dataBased on the findings of this symptomatic study, Annovis plans to conduct a pivotal disease-modifying
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 198% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.